Terms: = Skin cancer AND PMS1, hPMS1, 5378, ENSG00000064933, PMSL1, HNPCC3, DKFZp781M0253 AND Treatment
3 results:
1. Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.
Livingstone E; Gogas H; Kandolf-Sekulovic L; Meier F; Eigentler TK; Ziemer M; Terheyden PAM; Gesierich AH; Herbst RA; Kähler KC; Ziogas DC; Mijuskovic Z; Garzarolli M; Garbe C; Roesch A; Ugurel S; Gutzmer R; Grob JJ; Kiecker F; Utikal J; Windemuth-Kieselbach C; Eckhardt S; Zimmer L; Schadendorf D
Eur J Cancer; 2023 Sep; 190():112941. PubMed ID: 37482012
[TBL] [Abstract] [Full Text] [Related]
2. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract] [Full Text] [Related]
3. Gastrointestinal Behcet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review.
Wesner N; Drevon L; Guedon A; Fraison JB; Terrier B; Trad S; Kahn JE; Aouba A; Gillard J; Ponsoye M; Hanslik T; Gourguechon C; Liozon E; Laribi K; Rossignol J; Hermine O; Seksik P; Adès L; Carrat F; Fenaux P; Mekinian A; Fain O;
Leuk Lymphoma; 2019 Jul; 60(7):1782-1788. PubMed ID: 30457024
[TBL] [Abstract] [Full Text] [Related]
